Introduction
============

Heart failure is a costly, and fatal health problem in the world ([@b1-etm-0-0-7319]). In 2015, this disease affected approximately 40 million people in the world ([@b2-etm-0-0-7319]). Approximately 50% of the heart failure patients die in 5 years after diagnosis, but more than half of the advanced heart failure patients die within the first year following diagnosis ([@b3-etm-0-0-7319]). The cost to health-care of heart failure is up to 30 billion dollars per year in US alone. According to the statistical data, an urgent need is highlighted for identifying more accurate and available heart failure signatures with diagnostic and prognostic values.

Identification of gene signatures for complicated diseases such as heart failure and cancer is greatly important for diagnosis, prognosis, as well as developing personalized medicine and treatment strategy. In recent years, an increasing number of studies have proposed many biomarkers associated with heart failure. For example, cardiac troponin T, a biomarker of cardiomyocyte injury, has been demonstrated to be a predictor of side effects for heart failure patients ([@b4-etm-0-0-7319]). Moreover, Kusumoto *et al* ([@b4-etm-0-0-7319]) demonstrated that MYH7, ANXA2, IGFBP7, as well as DESM are promising candidate signatures of heart failure both in human and mouse. Frequently, these biomarkers cannot reflect the substrate relationship between genotypes and phenotypes, therefore they offer little information in the etiology of disorders, resulting in the urgent need of elucidating the potential pathogenesis of the disease as well as developing treatments. Additionally, reliable and simple measurements to detect the disorder earlier as well as to efficiently predict the prognosis still remain insufficient.

Thus, detecting novel biomarkers is of critical importance to understand and prevent heart failure. Long non-coding RNAs (lncRNAs) are a class of ncRNAs with \>200 nucleotides ([@b5-etm-0-0-7319]). LncRNAs have been implicated to play an important role, such as cell cycle, differentiation, and apoptosis ([@b6-etm-0-0-7319],[@b7-etm-0-0-7319]). Moreover, lncRNAs have been reported to competitively regulate biological pathways and to be closely related to heart-related diseases, for example, heart failure, and hypertrophy ([@b8-etm-0-0-7319]--[@b10-etm-0-0-7319]). Therefore, it is necessary to integratively analyze the joint effect of lncRNAs and pathway topologies. Moreover, extracting pathways competitively regulated by lncRNAs not only can provide novel insights into the potential mechanisms, but also help us to explore the functions of lncRNAs in a given disease ([@b11-etm-0-0-7319]). Currently, the functions of lncRNAs under a given disease condition have not been well revealed and a method for uncovering the lncRNA role is needed. Fortunately, key local subregions, not complete pathways, have been proposed to be more explainable to the molecular mechanisms of diseases ([@b12-etm-0-0-7319],[@b13-etm-0-0-7319]). It is noteworthy that detecting the sub-pathways instead of entire pathways might be more relevant for interpreting the related biological meaning and extracting the functions of lncRNAs. No report on lncRNA-modulated sub-pathways in heart failure patients is available.

In this study, to explore the etiology of heart failure, the expression of lncRNA-mRNA and pathway topologies were profiled to extract the lncRNAs competitively regulated sub-pathways in heart failure using the sub-pathway based strategy.

Materials and methods
=====================

### Gene expression data acquisition and pretreating

The gene expression profile on heart failure with the accession number E-GEOD-26887 ([@b14-etm-0-0-7319]) was recruited from Arrayexpress database, which was deposited in the platform of A-Affy-141-Affymetrix GeneChip Human Gene 1.0 AT Array \[HuGene-1-0-st-v1\]. In the E-GEOD-26887 ([@b14-etm-0-0-7319]), there were 19 patients with heart failure, and 5 controls from left ventricle cardiac biopsies. In the present work, a total of 24 subjects were used for subsequent analysis.

Then, pre-treatment for the original microarray profile was conducted. The specific steps contained background correction using robust multiarray average (RMA) approach ([@b15-etm-0-0-7319]), normalization by means of quartile ([@b16-etm-0-0-7319]), probe correction via MAS, and summarization of probe values through Medianpolish method. After probes were transformed to the human gene symbols, the final gene expression matrix (covering 18,715 genes) was established.

### Proposed scheme

Sub-pathway based method was used to detect sub-pathways competitively regulated by lncRNA in heart failure. This method included four steps: i) collection of candidate lncRNA-mRNA interactions; ii) using KEGG pathways as backbone, construction of condition-specific lncRNA competitively regulated pathways (LCRP) on the basis of lncRNA data, mRNA expression data, and lncRNA-mRNA interactions; iii) aligning competing lncRNAs and the interesting genes into the condition-specific LCRP, then locating sub-pathways in pathways and iv) evaluation of the significance of candidate sub-pathways.

### Collection of lncRNA-mRNA interactions

Firstly, lncRNA-miRNA interactions were recruited from StarBase database (version 2.0) ([@b17-etm-0-0-7319]), and mRNA-miRNA interactions were collected from the databases of mir2Disease, mirTarBase, TarBase, and miRecords (V4.0). On the basis of the common miRNAs, we collected candidate lncRNA-mRNA competitively regulated relationships. With the goal of guaranteeing data reliability, we filtered and reserved several candidate competing mRNAs for each lncRNA when they met the following criteria. The first criterion was that we utilized hypergeometric test to estimate the importance of the common miRNAs, and that the threshold of false discovery rate (FDR) was defined as 0.05. The second criterion was that Jaccard Coefficient of the common miRNAs were ordered at top 20%. Using these criteria, 7,693 candidate lncRNA-mRNA interactions covering 835 lncRNAs, and 1,749 mRNAs were obtained.

After that, we took the intersection between 18,715 genes of the microarray profile and 7,693 lncRNAs-mRNA relationships, we got a total of 1,605 mRNAs as well as 94 lncRNAs.

### Co-expression analysis for the lncRNA-mRNA interactions using Pearson correlation coefficient (PCC)

As known, PCC is an index of correlation between two variables, which ranges from −1 to 1 ([@b18-etm-0-0-7319]). Hence, in our study, PCC was used to assess the co-expression possibility for any pair of lncRNA-mRNA interactions on the basis of the matched lncRNA and mRNA data. After analysis using Fisher\'s r-to-Z transformation ([@b19-etm-0-0-7319]), those lncRNA-mRNA interactions that possess r value reaching a significant positive threshold were reserved (P\<0.05).

### Identification of informative pathways

KEGG is a database, which can provide reference knowledge to comprehensively understand cellular processes using pathway aligning ([@b20-etm-0-0-7319]). Thus, in our study, we downloaded all the KEGG background pathways based on KEGG database. After that, the mRNAs of the reconstructed lncRNA-mRNA interactions were mapped to the KEGG reference pathways, and then informative pathways were obtained. We used FDR to adjust the raw P-values by means of Benjamini-Hochberg procedure ([@b21-etm-0-0-7319]). We selected informative pathways using the criteria of FDR \<0.01.

### Establishment of condition-specific LCRP and hubs selection

Then, R package was used to transform the identified informative pathways above into undirected graphs which kept the structure of the original pathway ([@b12-etm-0-0-7319]). The lncRNAs in the lncRNA-mRNA interactions reweighted by PCC were aligned into the pathway graphs, which were as nodes via connecting to the mRNAs regulated by lncRNAs. Ultimately, the condition-specific LCRP were constructed, which contained lncRNA nodes as well as lncRNA-mRNA competitively regulated edges.

To our knowledge, hubs were frequently considered important within the biological network. Therefore, in order to extract significant lncRNAs, we concentrated on the hub lncRNAs in the LCRP. In this study, the top 10% of lncRNAs having the highest degree of connectivity were extracted and determined as the hub lncRNAs.

### Positioning sub-pathways competing regulated by lncRNAs

LncRNAs were considered as signature nodes, since these lncRNAs referred to the genes of interest and competing regulation. Integration of these lncRNAs with the topology features of LCRP is beneficial to effectively locate lncRNA-mediated subregions. The lncRNAs were embedded in the LCRP, and then 'lenient distance' similarity was used to identify the lncRNA-regulated sub-pathways based on the topology characteristics of the LCRP. In the current study, *n* (the number of molecules) = 1 and *s* (the number of nodes in the molecules in a pathway) = 8 were employed to extract the candidate sub-pathways.

### Assessment of significance of candidate sub-pathway

Wallenius approximation approach was applied to assess the significance of candidate sub-pathways based on BiasedUrn of R package ([@b22-etm-0-0-7319]), to further evaluate whether the candidate sub-pathways were competitively regulated by lncRNAs. During the evaluation process, the parameters below were used: the count of mRNAs of interest; the count of background mRNAs; the count of background mRNAs in a given sub-pathways; the number of interesting mRNAs enriched in this given sub-pathway; and the weight score of the sub-pathway. The weight was the strength of competing regulation by lncRNAs locating in this sub-pathway, which was computed using the equation described in a previous study ([@b11-etm-0-0-7319]). Next, FDR was used to correct the original P-values, and the significant sub-pathways were selected when on the threshold of FDR was set as 0.01.

Results
=======

### Co-expression analysis for lncRNA-mRNA interactions and informative pathways identification

Before identifying informative pathways, PCC was used to evaluate the co-expression possibility for lncRNA-mRNA interactions according to matched lncRNA as well as mRNA data. When the criteria were set at a P\<0.05, overall 44 lncRNAs, 165 mRNAs and 224 co-expressed interactions were extracted (data not shown). In order to detect seed pathways, these 165 mRNAs were then embedded into the background pathways. Finally, we obtained a total of 56 informative pathways when the FDR was set at 0.01 ([Table I](#tI-etm-0-0-7319){ref-type="table"}). Of note, the three most significant pathways were PI3K-Akt signaling pathway (FDR=2.81E-10), pathways in cancer (FDR=3.64E-10), and glioma (FDR=1.02E-09).

### Selecting lncRNA-regulated sub-pathways

Then, the 56 informative pathways were embedded in undirected graphs, and the 44 lncRNAs were mapped to the pathway graphs as nodes. After that, a condition-specific LCRP was built ([Fig. 1](#f1-etm-0-0-7319){ref-type="fig"}). To extract crucial lncRNAs of heart failure, a degree analysis was implemented for all nodes of the LCRP. According to degree distribution, a total of 4 hub lncRNAs were selected, including ERVK13-1, YLPM1, PDXDC2P, and LINC00482.

Based on the information of the LCRP, we discovered a total of 36 lncRNAs competitively regulating sub-pathways involved in 40 complete pathways when the FDR was \<0.01 ([Table II](#tII-etm-0-0-7319){ref-type="table"}). In advanced investigation, we mainly concentrated on the top three sub-pathways ([Fig. 2](#f2-etm-0-0-7319){ref-type="fig"}). The first most significant sub-pathway was path: 04010_1, which was a subpart of MAPK signaling pathway ([Fig. 2A](#f2-etm-0-0-7319){ref-type="fig"}). Subsequently, we further analyzed this sub-pathway, and we found that a total of 13 lncRNAs competitively regulated this subpart synergistically. Within these lncRNAs, two lncRNAs (PDXDC2P and NEXN-AS1), directly regulated three genes. In addition, MYC was coordinately regulated by three lncRNAs (CRYM-AS1, MAL2, and UBXN8). Moreover, AKT3 was also simultaneously regulated by three lncRNAs (ERVK13-1, YLPM1, and PDXDC2P).

The second significant subregion was path: 04012-1, an important subpart in ErbB signaling pathway ([Fig. 2B](#f2-etm-0-0-7319){ref-type="fig"}). Similar to the first significant sub-pathway, gene AKT3 was also simultaneously regulated by three lncRNAs (ERVK13-1, YLPM1, and PDXDC2P).

The third sub-pathway, path: 04062_2, was a part of chemokine signaling pathway ([Fig. 2C](#f2-etm-0-0-7319){ref-type="fig"}). Similar to the first and the second significant sub-pathways, gene AKT3 was also simultaneously regulated by three lncRNAs (ERVK13-1, YLPM1, and PDXDC2P). Notably, lncRNA UBXN8 competitively regulated three genes (KRAS, LYN, and SHC1). Thus, these results demonstrated that this approach could identify biological meaningful sub-pathways, and highlighted some critical lncRNAs in heart failure condition.

Discussion
==========

Currently, alteration of lncRNA competitively regulated functions may result in the occurrence and progression of diseases, but, a better understanding of this regulatory mechanism may give more and better opportunities for developing new therapies. Hence we constructed an LCRP for the informative pathways, and integrated the lncRNAs with the topology features of LCRP. Normally, comparing with the entire pathways, sub-pathways may be more explainable to the molecular mechanisms underlying disorders. Consequently, detecting the sub-pathways which were regarded to be more possibly disrupted pathways from the LCRP would be the best means to discriminate the heart failure group from the control group.

Thus, an LCRP was constructed with 36 lncRNAs, 102 mRNA nodes and 40 pathways by combining gene expression profile, lncRNA data, pathway information and PCC related analyses. Finally, based on the information of the LCRP, a total of 36 lncRNAs competitively regulating sub-pathways involved in 40 complete pathways were identified. Among these 40 pathways, we mainly concentrated on the top three sub-pathways that competitively regulated by lncRNAs, including path: 04010_1, which was a subpart of MAPK signaling pathway, path: 04012-1, an important subpart in ErbB signaling pathway, and path: 04062_2, a part of chemokine signaling pathway.

Taking MAPK signaling pathways as examples to discuss, the MAPK signaling pathway has been implicated to control myocyte growth that responds to pathological stimuli in the heart ([@b23-etm-0-0-7319]). Heart failure is considered to be a remodeling process of myocyte cells, and cellular as well as extracellular factors participate in this remodeling process to further cause the changes in myocardial structures and functions. Matrix metalloproteinases (MMPs) are the factors participating in this remodeling process. Significantly, MMPs secretion has been reported to be dependent on MAPK or MAPK signaling pathway ([@b24-etm-0-0-7319],[@b25-etm-0-0-7319]). Thus, we speculate that a close relationship exists between the heart failure and MAPK signaling pathway.

Of note, in the first, second, and third most significant sub-pathways, gene AKT3 was simultaneously regulated by three lncRNAs (ERVK13-1, YLPM1, and PDXDC2P). Moreover, ERVK13-1, YLPM1, and PDXDC2P were all hubs in the LCRP. YLPM1 was also termed as ZAP3. A former study has demonstrated that the highest expression of ZAP3 seems to be in brain, heart and kidneys ([@b26-etm-0-0-7319]). Of note, ZAP3 has been implicated to decrease telomerase activity ([@b27-etm-0-0-7319]). Further, telomerase ablation can cause the occurrence of heart failure ([@b28-etm-0-0-7319]). Thus, we infer that lncRNA YLPM1 might play crucial roles in the development of heart failure, partially via regulating the telomerase activity. Although few reports have suggested the link between lncRNAs (ERVK13-1, or PDXDC2P) and heart failure, we found these lncRNAs regulated the common gene AKT3 in our study. AKT3 is one of the three isoforms of AKT which mediates cardiac growth, cell death, and myocardial angiogenesis in cardiac myocytes ([@b29-etm-0-0-7319]). Moreover, coronary vasculature, and cell death are essential for the maintenance of the contractile function, especially in heart failure ([@b30-etm-0-0-7319]). Accordingly, we infer that lncRNAs (ERVK13-1 and PDXDC2P) have indirect relationships with heart failure.

The current study had several limitations. The study population was small. The lack of verification of microarray results by means of quantitative real-time PCR technique or western blot based on animal or patient tissues was another important drawback. Thus, further studies in larger study samples are necessary to confirm these findings in terms of the efficiency as diagnostic or prognostic biomarkers of heart failure.

In conclusion, we applied sub-pathway-based analysis by introducing the concept of pathway topology, lncRNA data, and subregion of pathways. The importance of this method is that it can help to understand the etiology of diseases, and provide important insight into the functions of lncRNAs in heart failure. Based on the results, we showed that MAPK signaling pathway, ErbB signaling pathway, as well as chemokine signaling pathway were the significant sub-pathways for heart failure. Nevertheless, the verification using other datasets is implemented to demonstrate that these sub-pathways are useful in classifying heart failure and normal group.
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###### 

The seed pathways.

  Pathways                                                                 False discovery rate (FDR)
  ------------------------------------------------------------------------ ----------------------------
  hsa05211: Renal cell carcinoma                                           8.81E-05
  hsa04066: HIF-1 signaling pathway                                        7.99E-05
  hsa05169: Epstein-Barr virus infection                                   7.13E-08
  hsa05210: Colorectal cancer                                              7.07E-06
  hsa05215: Prostate cancer                                                5.94E-11
  hsa05219: Bladder cancer                                                 5.44E-09
  hsa05220: Chronic myeloid leukemia                                       4.75E-08
  hsa04110: Cell cycle                                                     4.56E-07
  hsa04510: Focal adhesion                                                 4.45E-05
  hsa04012: ErbB signaling pathway                                         4.20E-08
  hsa05200: Pathways in cancer                                             3.64E-10
  hsa05222: Small cell lung cancer                                         3.64E-08
  hsa05218: Melanoma                                                       3.31E-07
  hsa05223: Non-small cell lung cancer                                     2.92E-07
  hsa04151: PI3K-Akt signaling pathway                                     2.81E-10
  hsa05203: Viral carcinogenesis                                           2.32E-06
  hsa04115: p53 signaling pathway                                          2.09E-07
  hsa05120: Epithelial cell signaling in *Helicobacter pylori* infection   1.90E-06
  hsa05161: Hepatitis B                                                    1.55E-08
  hsa05212: Pancreatic cancer                                              1.52E-07
  hsa05213: Endometrial cancer                                             1.50E-05
  hsa04722: Neurotrophin signaling pathway                                 1.12E-05
  hsa05214: Glioma                                                         1.02E-09
  hsa04150: mTOR signaling pathway                                         9.92E-03
  hsa04620: Toll-like receptor signaling pathway                           8.55E-03
  hsa04810: Regulation of actin cytoskeleton                               7.55E-03
  hsa05133: Pertussis                                                      5.90E-03
  hsa05152: Tuberculosis                                                   5.67E-03
  hsa04520: Adherens junction                                              5.17E-03
  hsa04662: B cell receptor signaling pathway                              4.83E-03
  hsa04666: Fc gamma R-mediated phagocytosis                               3.73E-03
  hsa04540: Gap junction                                                   3.29E-03
  hsa04914: Progesterone-mediated oocyte maturation                        3.09E-03
  hsa05162: Measles                                                        2.66E-03
  hsa05160: Hepatitis C                                                    2.52E-03
  hsa03008: Ribosome biogenesis in eukaryotes                              2.37E-03
  hsa04740: Olfactory transduction                                         2.36E-03
  hsa04728: Dopaminergic synapse                                           2.28E-03
  hsa04730: Long-term depression                                           1.92E-03
  hsa04350: TGF-β signaling pathway                                        1.79E-03
  hsa05166: HTLV--I infection                                              1.66E-03
  hsa04910: Insulin signaling pathway                                      9.71E-04
  hsa04912: GnRH signaling pathway                                         8.83E-04
  hsa04062: Chemokine signaling pathway                                    8.78E-04
  hsa05168: Herpes simplex infection                                       7.27E-04
  hsa04720: Long-term potentiation                                         6.21E-04
  hsa04330: Notch signaling pathway                                        5.84E-04
  hsa04660: T cell receptor signaling pathway                              4.37E-04
  hsa05142: Chagas disease (American trypanosomiasis)                      4.37E-04
  hsa05216: Thyroid cancer                                                 3.72E-04
  hsa05145: Toxoplasmosis                                                  2.67E-04
  hsa04310: Wnt signaling pathway                                          2.38E-04
  hsa04621: NOD-like receptor signaling pathway                            2.27E-04
  hsa05221: Acute myeloid leukemia                                         2.27E-04
  hsa04725: Cholinergic synapse                                            1.74E-04
  hsa04010: MAPK signaling pathway                                         1.52E-04

###### 

Sub-pathways list based on FDR\<0.01

  Pathway IDs   Pathway name                           FDR
  ------------- -------------------------------------- ----------
  04010_1       MAPK signaling pathway                 2.80E-16
  04012_1       ErbB signaling pathway                 5.35E-16
  04062_2       Chemokine signaling pathway            1.96E-15
  04110_1       Cell cycle                             5.16E-15
  04115_1       p53 signaling pathway                  4.50E-15
  04151_1       PI3K-Akt signaling pathway             4.53E-15
  04310_1       Wnt signaling pathway                  4.62E-15
  04510_1       Focal adhesion                         4.87E-15
  04722_1       Neurotrophin signaling pathway         1.88E-14
  05161_1       Hepatitis B                            3.28E-14
  05166_1       HTLV--I infection                      5.96E-14
  05168_1       Herpes simplex infection               7.40E-14
  05169_1       Epstein-Barr virus infection           1.56E-13
  05200_1       Pathways in cancer                     5.33E-13
  05212_1       Pancreatic cancer                      5.92E-13
  05214_1       Glioma                                 2.06E-12
  05215_1       Prostate cancer                        5.99E-12
  05218_1       Melanoma                               6.87E-11
  05222_1       Small cell lung cancer                 6.85E-11
  05223_1       Non-small cell lung cancer             2.16E-10
  04728_1       Dopaminergic synapse                   5.61E-10
  05203_2       Viral carcinogenesis                   7.29E-10
  04066_1       HIF-1 signaling pathway                1.61E-09
  05152_2       Tuberculosis                           2.54E-09
  04720_1       Long-term potentiation                 7.51E-09
  04810_3       Regulation of actin cytoskeleton       8.92E-09
  04662_1       B cell receptor signaling pathway      2.21E-08
  05145_1       Toxoplasmosis                          3.08E-08
  03008_1       Ribosome biogenesis in eukaryotes      7.25E-08
  05210_1       Colorectal cancer                      1.79E-07
  05220_1       Chronic myeloid leukemia               9.38E-07
  05221_1       Acute myeloid leukemia                 2.29E-06
  04620_1       Toll-like receptor signaling pathway   1.61E-06
  04330_1       Notch signaling pathway                3.67E-06
  04660_2       T cell receptor signaling pathway      8.54E-06
  05213_1       Endometrial cancer                     9.12E-06
  04910_1       Insulin signaling pathway              3.27E-05
  05160_1       Hepatitis C                            1.59E-05
  05162_2       Measles                                9.14E-05
  04350_1       TGF-β signaling pathway                1.09E-04
